Business Context and Reporting Period
Company: Novo Nordisk A/S
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Date: May 5, 2026
Subject: Conclusion of a specific tranche of the company's share repurchase programme.
Key Financial Metrics
This filing reports on capital allocation activities rather than operating performance. Key metrics include:
- Repurchase Programme Total Authorization: Up to DKK 15 billion over a 12-month period starting February 4, 2026.
- Specific Tranche Authorization: Up to DKK 3.8 billion for the period February 4, 2026, to May 4, 2026.
- Total Shares Repurchased (Tranche): 14,759,179 B shares.
- Total Value Repurchased (Tranche): DKK 3,799,999,990.
- Average Purchase Price: DKK 257.47 per B share.
- Treasury Shares Held: 32,148,978 B shares (0.7% of total share capital).
- Total Share Capital: 4,465,000,000 A and B shares (including treasury shares).
Material Changes
The filing details the completion of a specific share buyback tranche. Since the last announcement on April 27, 2026, the company executed six additional transactions between April 28 and May 4, 2026. These transactions brought the accumulated purchase value to approximately DKK 3.8 billion, effectively concluding the initial three-month phase of the broader 12-month programme.
Guidance, Outlook, and Management Commentary
Outlook: Novo Nordisk expects to continue repurchasing B shares for an amount up to DKK 15 billion during the remaining 12-month period beginning February 4, 2026.
Management Commentary: The company reaffirmed its status as a leading global healthcare company focused on defeating serious chronic diseases, employing approximately 68,800 people across 80 countries. The repurchase programme is executed in accordance with EU Market Abuse Regulation (MAR) Safe Harbour Rules.
Investor Verification Checklist
- Verify the remaining authorization under the DKK 15 billion programme (approximately DKK 11.2 billion).
- Confirm the current market price of B shares relative to the DKK 257.47 average purchase price.
- Review the company's liquidity position to ensure capacity for the remaining buyback commitments.
- Check for any subsequent filings regarding the execution of the remaining 12-month programme.